SCHEMBL10134880

SCHEMBL10134880

c1cc2c(s1)c(NC1CCNCC1)nc1cc(-c3nnn[nH]3)ccc12

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 6/20 0.43
PRKCI P41743 11/20 0.41
KCNH2 Q12809 1/20 0.38
PIM1 P11309 1/20 0.36
CSNK2B P67870 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPT P10636 1/20 0.36
RECQL P46063 1/20 0.36
BLM P54132 1/20 0.36
HBB P68871 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132297 0.93 CSNK2A1 (0.51) CSNK2A1PRKCIPIM1CSNK2BPIM2
SCHEMBL10132255 0.81 CSNK2A1 (0.48) CSNK2A1PIM1CSNK2BPIM2
SCHEMBL10132272 0.77 CSNK2A1 (0.44) CSNK2A1
SCHEMBL10132264 0.76 CSNK2A1 (0.43) CSNK2A1
SCHEMBL10134866 0.76 CSNK2A1 (0.59) CSNK2A1
SCHEMBL10134871 0.76 CSNK2A1 (0.58) CSNK2A1PIM1CSNK2BPIM2
SCHEMBL10134842 0.76 CSNK2A1 (0.59) CSNK2A1PIM1CSNK2BPIM2
SCHEMBL13688040 0.76 CSNK2A1 (0.43) CSNK2A1CSNK2B
SCHEMBL10134882 0.74 CSNK2A1 (0.59) CSNK2A1KCNH2CSNK2B
SCHEMBL10134883 0.74 LMNA (0.40) CSNK2A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885PRKCI 25/4885KCNH2 3852/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885PRKCI 25/4885KCNH2 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.